Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. PPM Ventures and Triton – acquisition of Pharmacia Diagnostics
Mandate

PPM Ventures and Triton – acquisition of Pharmacia Diagnostics

May 12, 2005

Triton, the European private equity firm, and PPM Ventures Ltd, the private equity business within Prudential Corporation plc, the UK financial services group, has agreed to acquire Pharmacia Diagnostics AB, the Swedish based in-vitro allergy and autoimmune diagnostic testing business of Pfizer Inc, the US-based health care company, for USD 575m.

Vinge acted for Triton and PPM Ventures Ltd.

Johan Cederlund, Christina Kokko (responsible partners)
Sara Mindus (associate)

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

 Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

 Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025